BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25805812)

  • 1. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
    Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
    Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
    Bruserud Ø; Reikvam H; Fredly H; Skavland J; Hagen KM; van Hoang TT; Brenner AK; Kadi A; Astori A; Gjertsen BT; Pendino F
    Oncotarget; 2015 Feb; 6(5):2794-811. PubMed ID: 25605239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
    Astori A; Fredly H; Aloysius TA; Bullinger L; Mansat-De Mas V; de la Grange P; Delhommeau F; Hagen KM; Récher C; Dusanter-Fourt I; Knappskog S; Lillehaug JR; Pendino F; Bruserud Ø
    Oncotarget; 2013 Sep; 4(9):1438-48. PubMed ID: 23988457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
    Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
    Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m
    Naren D; Yan T; Gong Y; Huang J; Zhang D; Sang L; Zheng X; Li Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):33-47. PubMed ID: 32880751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.
    Licciulli S; Cambiaghi V; Scafetta G; Gruszka AM; Alcalay M
    Leukemia; 2010 Feb; 24(2):429-37. PubMed ID: 20010624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia.
    Taskesen E; Staal FJ; Reinders MJ
    BMC Bioinformatics; 2015; 16 Suppl 4(Suppl 4):S4. PubMed ID: 25734857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia.
    Valencia A; Román-Gómez J; Cervera J; Such E; Barragán E; Bolufer P; Moscardó F; Sanz GF; Sanz MA
    Leukemia; 2009 Sep; 23(9):1658-66. PubMed ID: 19387464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
    Tao YF; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Xu LX; Li ZH; Wang NN; Du XJ; Sun LC; Zhao H; Fang F; Su GH; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    Int J Mol Med; 2014 Dec; 34(6):1505-15. PubMed ID: 25319049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
    Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
    Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients' prognosis.
    Cardona-Echeverry A; Prada-Arismendy J
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3097-3109. PubMed ID: 32980885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pontin is a critical regulator for AML1-ETO-induced leukemia.
    Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
    Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
    Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
    Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
    PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.